⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660763 | 0.83 | GPR84 (0.43) | — | |
| SCHEMBL13677532 | 0.79 | GPR84 (0.47) | — | |
| SCHEMBL6929568 | 0.79 | — | — | |
| SCHEMBL21214838 | 0.78 | NOTUM (0.58) | — | |
| SCHEMBL24416393 | 0.78 | ABL1 (0.37) | — | |
| SCHEMBL9686886 | 0.77 | — | — | |
| SCHEMBL1161397 | 0.77 | — | — | |
| SCHEMBL2595424 | 0.77 | — | — | |
| SCHEMBL9494732 | 0.77 | — | — | |
| Bromide SCHEMBL1161612 | 0.77 | NOTUM (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| WO-2025011476-A1 | INDAZOLE DERIVATIVE OR PHARMACEUTICAL SALT THEREOF AND USE THEREOF | 浙江大学 | 2025-01-16 | — | — | WO | disclosed |
| CN-119219609-A | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof | 浙江大学 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116891460-A | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof | 浙江大学 | 2023-10-17 | — | — | CN | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| WO-2023275199-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| US-20070299065-A1 | Tetrahydropyran Derivatives as Antidiabetics | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299065-A1 | Tetrahydropyran Derivatives as Antidiabetics | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007076228-A2 | 2-(IH-THIENO [3,2-C] PYRAZOL-3YL)-IH-INDOLE DERIVATIVES AND RELATED COMPOUNDS AS TEC KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AND IMMUNOLOGICAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |